RO7046015, Placebo Prasinezumab
BN44715
Phase 3 small_molecule active
Quick answer
RO7046015, Placebo Prasinezumab for Early-Stage Parkinson’s Disease (PD) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Early-Stage Parkinson’s Disease (PD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active